Sort   by:  
 Page size 
UnknownModeling integration site data for safety assessment with MELISSA.
Not available
S-EPMC12375041 | biostudies-literature
UnknownSynergies, Discrepancies, and Action Priorities: A Statewide Engagement Study to Strengthen Clinical Research in Cerebral Palsy.
Not available
S-EPMC12022003 | biostudies-literature
GenomicsBIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues
C-MYC (henceforth MYC) is one of the most frequently overexpressed oncogenes in human cancer and even modestly deregulated MYC expression can initiate ectopic proliferation in many post-mitotic, terminally differentiated cell types in vivo. Metazoan organisms have consequently evolved a number of me...
ORGANISM(S): Homo sapiens 
2015-05-18 | E-GEOD-59001 | biostudies-arrayexpress
TranscriptomicsGene expression in human endometrial cancer tissues and serous papillary endometrial cancer cell line, SPAC-1L, treated by STAT1-siRNA and/or IFN-gamma
Endometrial cancer is one of the most common gynecologic malignancies, and patients with high grade disease, especially serous papillary subtype (SPEC) are often related to the poor outcomes. Recent genome-wide analyses have revealed that SPEC exhibits gene expression profiles that are distinct from...
ORGANISM(S): Homo sapiens 
2014-03-20 | E-GEOD-56026 | biostudies-arrayexpress
GenomicsBRCA_SNV_SR - samples
single nucleotide variant calls from somatic sniper, vcf format. input for subclonal reconstruction
EGAD00001003753 | EGA
GenomicsCPCG BRCA2 - samples
Aligned sequence data from 14 Prostate cancer samples with BRCA2 mutations
EGAD00001002739 | EGA
GenomicsCPCG-BRCA-ARRAY
Raw Array data from the CPCGene BRCA study
EGAD00010001196 | EGA
GenomicsBRCA_SNV - samples
single nucleotide variant calls from somatic sniper, vcf format
EGAD00001003752 | EGA
GenomicsBRCA_SV - samples
structural variant calls from Delly, vcf format
EGAD00001003754 | EGA
GenomicsMED12L Gene Alterations Define Aggressive BRCA2-Mutant Prostate Cancers
Germline mutation of BRCA2 increases the lifetime risk of developing prostate cancer (PCa) by over 700%. BRCA2-mutant PCa have poorer prognosis than sporadic PCa, with rapid development of metastatic, castrate-resistant prostate cancer (mCRPC) and 5-year cancer-specific survival rates of ~50-60%1-4....
EGAS00001001615 | EGA
Sort   by:  
 Page size